Journal Information
Vol. 224. Issue 1.
Pages 65-66 (January 2024)
Vol. 224. Issue 1.
Pages 65-66 (January 2024)
Correspondence
Full text access
Impact of strict isolation measures, surgical activity and antimicrobial use on Clostridioides difficile infection during COVID-19
Impacto de las medidas de aislamiento estricto, actividad quirúrgica y uso de antimicrobianos en la infección por Clostridioides difficile durante COVID-19
Visits
279
J. Enaa,
Corresponding author
j.ena@umh.es

Corresponding author.
, C. Martinez-Peinadoa, V. Vallsb
a Servicio de Medicina Interna, Hospital Marina Baixa, Villajoyosa, Spain
b Servicio de Medicina Preventiva, Hospital Universitario de San Juan, San Juan de Alicante, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Trends in C. difficile hospital infections, surgical activity and antimicrobial usage 2020-2022.
Full Text
Dear Director,

On January 30, 2020, the World Health Organization (WHO) Director-General declared that the COVID-19 outbreak constituted a Public Health Emergency of International Concern.1 During the initial phase of the COVID-19 pandemic, hospitals completely transformed their activity to provide care to patients with SARS-CoV-2 infection. The pandemic period led to a dramatic increase in infection control measures, a significant reduction in surgical activity, and possibly modifications in antimicrobial prescription patterns.2–4 We hypothesized that all these factors could have contributed to significant changes in Clostridioides difficile epidemiology. Therefore, we carried out a retrospective study to assess the trends in C. difficile infections and their association with antimicrobial usage and surgical activity at our institution.

Our hospital is a 250-bed facility on the East Coast of Spain that belongs to the National Health System and provides care to 190,000 inhabitants. The first cases of COVID-19 were diagnosed at our institution on March 13, 2020. We reviewed the records from the Clinical Microbiology, Pharmacy departments, and hospital administrative data from January 1, 2020, to December 31, 2022. We estimated the rates of C. difficile infections, surgical activity (elective and emergency interventions with general anesthesia), and antimicrobial usage in daily defined doses (DDD). C. difficile infection was identified in stool samples using polymerase chain reaction (PCR) systems either with FilmArray Gastrointestinal Panel (Biofire Diagnostics, LLC, Salt Lake City, Utah, USA), or GeneXpert System (Xpert© C. difficile BT. Cepheid AB, Solna, Sweden).

In the study period, 164 patients, mean age 61.1 years [range three months to 96 years], 42% males, had C. difficile infection. There were no cases of C. difficile infections due to ribotype 027. C. difficile infections per 10,000 admissions rose from 2020 to 2022, starting from 18.03, 41.40, and finishing at 72.3, respectively (Table 1). Compared with the following year, the prevented fraction for C. difficile in 2020 was 56.44% (95% Confidence interval: 27.59–73.79%, P < .001). There were no significant reductions in surgical activity rates (P = .17) or antimicrobial consumption rates (P = .30) between the years 2020 and 2021 (Table 1).

Table 1.

Trends in C. difficile hospital infections, surgical activity and antimicrobial usage 2020-2022.

Year  Hospital admissions  COVID-19 cases  No. of stool samples  C.difficile cases  C difficile per 10,000 admissions  C difficile per 1000 stool samples  No. of elective surgery  No. of emergency surgery  Antimicrobial usage 
                  Total DDD 
2020  11,643  568  1568  21  18  13  3428  1472  9689.36 
2021  12,317  906  1907  51  41  27  3791  1535  10,101.95 
2022  12,724  916  1923  92  72  48  4520  1569  10,386.96 

DDD: daily defined dose.

However, C. difficile infections occurred more often in patients with COVID-19 than in subjects admitted to the hospital due to other conditions. In the study period, a total of 20 out of 2390 patients with COVID-19 had C. difficile infection (83.68 per 10,000 admissions), whereas, in patients with no COVID-19 infection, the incidence rate was 41.98 per 10,000 admissions (RR 1.83; 95% Confidence interval: 1.15–2.92; P = 0.009).

According to our hypotheses, we have observed that strict infection control measures taken in 2020 had a significant impact on C. difficile infections. Studies examining C. difficile infection trends during COVID-19 epidemics showed discrepant results. Some studies showed a reduction in C. difficile rates related to infection control strategies,5,6 others did not report significant changes,7 and some demonstrated an increase in C. difficile rates.8 Neither of the studies reported surgical activity information during the study periods. However, all of them showed greater use of antimicrobials during COVID-19 waves. Regarding the specific susceptibility of patients with COVID-19 to acquire C. difficile infection, a study reported an increased risk by a factor of two, likewise to our report.9 A case-control study identified steroid use, hospitalization in the last two months, and receiving antimicrobials during the hospital stay as the independent factors associated with C. difficile infection in patients with COVID-19.10

Our study has some limitations. Firstly, data were generated from a secondary-level hospital instead of a tertiary care facility. Secondly, data were obtained from a hospital in Spain, and the results would not be generalizable to other countries. Nevertheless, we consider there was a small risk of internal bias, and our results could be extrapolated to centers with similar characteristics.

In summary, infection control measures, like enhanced hand hygiene, isolation precautions, use of personal protection equipment, and environmental cleaning, helped to minimize cross-transmission and contributed to reducing C. difficile rates during the first pandemic wave.

References
[1]
Eurosurveillance editorial team.
Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern.
Euro Surveill, 25 (2020), pp. 200131e
[2]
A.T.A. Qarawi, S.J. Ng, A. Gad, M.N. Luu, T.M.A. Al-Ahdal, et al.
Study protocol for a global survey: awareness and preparedness of hospital staff against coronavirus disease (COVID-19) outbreak.
Front Public Health, 9 (2021),
[3]
T. Whiteside, E. Kane, B. Aljohani, M. Alsamman, A. Pourmand.
Redesigning emergency department operations amidst a viral pandemic.
Am J Emerg Med, 38 (2020), pp. 1448-1453
[4]
A.M. Cattelan, L. Sasset, E. Di Meco, S. Cocchio, F. Barbaro, et al.
An integrated strategy for the prevention of SARS-CoV-2 infection in healthcare workers: a prospective observational study.
Int J Environ Res Public Health, 17 (2020), pp. 5785
[5]
S. Voona, H. Abdic, R. Montgomery, A. Clarkson, H. Twitchell, T. Hills, et al.
Impact of COVID-19 pandemic on prevalence of Clostridioides difficile infection in a UK tertiary centre.
[6]
M. Ponce-Alonso, J. Sáez de la Fuente, A. Rincón-Carlavilla, P. Moreno-Nunez, L. Martínez-García, et al.
Impact of the coronavirus disease 2019 (COVID-19) pandemic on nosocomial Clostridioides difficile infection.
Infect Control Hosp Epidemiol, 42 (2021), pp. 406-410
[7]
S. Yadlapati, S.A. Jarrett, K.B. Lo, J. Sweet, T.A. Judge.
Examining the rate of Clostridioides (Formerly Clostridium) difficile infection pre- and post-COVID-19 pandemic: an institutional review.
Cureus, 13 (2021), pp. e20397
[8]
S. Zouridis, M. Sangha, P. Feustel, S. Richter.
Clostridium difficile infection rates during the pandemic in New York capital area: a single-center study.
Cureus, 15 (2023), pp. e37576
[9]
S. Vázquez-Cuesta, M. Olmedo, E. Reigadas, L. Alcalá, M. Marín, P. Muñoz, et al.
Clostridioides difficile infection epidemiology and clinical characteristics in COVID-19 pandemic.
Front Med (Lausanne), 9 (2022),
[10]
G. Granata, A. Bartoloni, M. Codeluppi, I. Contadini, F. Cristini, M. Fantoni, On Behalf Of The CloVid Study Group, et al.
The burden of Clostridioides difficile infection during the COVID-19 pandemic: a retrospective case-control study in Italian hospitals (CloVid).
J Clin Med, 9 (2020), pp. 3855
Idiomas
Revista Clínica Española (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?